Pfizer Inc. $PFE Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 44.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 573,500 shares of the biopharmaceutical company’s stock after selling 467,425 shares during the quarter. Gabelli Funds LLC’s holdings in Pfizer were worth $13,902,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC lifted its holdings in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after buying an additional 388 shares in the last quarter. Citizens National Bank Trust Department increased its position in shares of Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 395 shares during the period. Able Wealth Management LLC raised its stake in shares of Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 413 shares in the last quarter. Trust Co of the South boosted its holdings in Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 441 shares during the period. Finally, Charter Oak Capital Management LLC boosted its holdings in Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 444 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Guggenheim increased their price target on Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, November 24th. Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley decreased their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.39.

Pfizer Stock Down 1.0%

Shares of NYSE:PFE opened at $25.78 on Tuesday. The firm has a 50 day simple moving average of $25.21 and a 200-day simple moving average of $24.71. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $146.55 billion, a PE ratio of 14.99 and a beta of 0.46.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 7th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend was Friday, November 7th. Pfizer’s payout ratio is presently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.